Avid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business Operations
November 29 2017 - 8:05AM
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine
Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced
the appointment of Tracy L. Kinjerski as vice president of business
operations. Ms. Kinjerski is a senior business development
executive with more than 17 years of experience in the
biopharmaceutical industry, almost all of which have been focused
in contract development and manufacturing. In her new role, she
will be charged with driving growth in Avid’s contract development
and manufacturing organization (CDMO) business through the
strategic expansion and diversification of the company’s commercial
and clinical client base. Her responsibilities will span business
development, project management and marketing.
Ms. Kinjerski most recently served as senior
director of global business development at CMC Biologics, a global
CDMO. In that role, her efforts spearheading business development
and client relationship management generated significant new
business growth in less than one year of joining the company. Prior
to CMC Biologics, Ms. Kinjerski spent nearly five years with
Fujifilm Diosynth Biotechnologies, the global CDMO division for
Fujifilm. During her tenure, she served as director of
commercial development focused on the East Coast of the US, helping
to grow the company’s clinical and commercial business through new
client engagements spanning global pharmaceutical companies,
biotechnology companies of all sizes and government projects. Ms.
Kinjerski, who holds a master’s degree in biomedical sciences, has
also served in business and commercial development leadership
positions at Althea Technologies and Avecia Biologics Billingham
(since acquired by Fujifilm Diosynth), two fully-integrated CDMOs
serving the pharmaceutical and biotechnology industries.
“We feel fortunate to add an individual with the
talent and experience of Tracy to our expanding team of CDMO
industry veterans,” said Roger Lias, Ph.D., president of Avid
Bioservices. “At Avid, we are acutely focused on positioning
the company as a leading pure play CDMO and growing revenues, while
at the same time strategically diversifying our client base and
service offering. We believe that Tracy, with her proven
track record of success in CDMO business development and client
relations will play a key role in helping the company achieve these
goals.”
Avid Bioservices was established as Peregrine’s
internal biologics manufacturing and development group, and began
formal operations in January 2002. The company has grown from
an internal support operation to a full service CDMO serving
leading biopharma companies. Avid was recently recognized as a
leading CDMO by Life Science Leader as a recipient of multiple 2017
Contract Manufacturing Leadership Awards for Quality, Reliability,
Capabilities, Expertise and Compatibility. The company has an
outstanding regulatory inspection history, including 12 years of
commercial manufacturing and state-of-the-art cGMP manufacturing
facilities.
About Avid Bioservices, Inc.Avid Bioservices, a
wholly owned subsidiary of Peregrine Pharmaceuticals, provides a
comprehensive range of process development, high quality cGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 20 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, including 12
years of commercial manufacturing for products sold in 18
countries, Avid's services include cGMP clinical and commercial
product manufacturing, purification, bulk packaging, lot release
and stability testing, regulatory strategy, submission and support.
The company also provides a variety of process development
activities, including cell line development and optimization, cell
culture and feed optimization, analytical methods development,
qualification/validation, process and product characterization. For
more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals, Inc.Peregrine
Pharmaceuticals, Inc. is a company transitioning from an R&D
focused business to a pure play contract development and
manufacturing organization (CDMO). Peregrine's in-house CDMO
services, including cGMP manufacturing and development
capabilities, are provided through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com).
The company is pursuing to license or sell its
proprietary R&D assets, including its lead immunotherapy
candidate, bavituximab, which is currently being evaluated in
clinical trials in combination with immune stimulating therapies
for the treatment of various cancers. For more information,
please visit www.peregrineinc.com.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024